Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

BACKGROUND: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure (HF) and cardiomyopathy (CM). However, clinical trials may underestimate HF/CM risk because they enroll younger subjects with fewer...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Ezaz, Ghideon, Long, Jessica B., Gross, Cary P., Chen, Jersey
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2014
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959671/
https://ncbi.nlm.nih.gov/pubmed/24584736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000472
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki